Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors

Fas/APO‐1 (CD95) is a cell surface receptor that mediates apoptosis when it reacts with Fas ligand (FasL) or Fas antibody. We previously reported that Fas expression is predominantly induced in perinecrotic glioma cells, suggesting that Fas induction is associated with apoptosis and necrosis formation, a histological hallmark of glioblastomas. In this study, we assessed the expression of FasL in 10 glioblastoma cell lines and in 14 astrocytic brain tumors (three low‐grade astrocytomas and 11 glioblastomas). Reverse transcriptase (RT)‐PCR revealed that all glioblastoma cell lines and primary astrocytic brain tumors express FasL. Immunohistochemically, FasL was predominantly expressed on the plasma membrane of glioma cells. These results suggest that FasL expression is common in human astrocytic brain tumors and may cause apoptosis of glioma cells if Fas expression is induced.

[1]  J. Mountz,et al.  Characterization of human Fas gene. Exon/intron organization and promoter region. , 1995, Journal of immunology.

[2]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[3]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[4]  P. Wen,et al.  Malignant gliomas , 2004, Current neurology and neuroscience reports.

[5]  T. Koji,et al.  Immunohistochemical Localization of Fas Antigen in Paraffin Sections with Rabbit Antibodies Against Human Synthetic Fas Peptides. , 1994 .

[6]  C. Smith,et al.  Fas ligand mediates activation-induced cell death in human T lymphocytes , 1995, The Journal of experimental medicine.

[7]  P. Liberski,et al.  Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks , 1995, Acta Neuropathologica.

[8]  T. Loughran,et al.  Clonal diseases of large granular lymphocytes. , 1993, Blood.

[9]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[10]  J. Inazawa,et al.  Human Fas ligand: gene structure, chromosomal location and species specificity. , 1994, International immunology.

[11]  P. Kleihues,et al.  Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme , 1996, Acta Neuropathologica.

[12]  M. Weller,et al.  Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. , 1994, The Journal of clinical investigation.

[13]  Susan M. Chang,et al.  Necrosis as a prognostic factor in glioblastoma multiforme , 1996, Cancer.

[14]  P. Chappuis,et al.  A simple p53 functional assay for screening cell lines, blood, and tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Plate,et al.  Angiogenesis in malignant gliomas , 1995, Glia.

[16]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[17]  A. Chiò,et al.  Apoptosis and cell proliferation in human neuroepithelial tumors , 1995, Neuroscience Letters.

[18]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[19]  J. Menonna,et al.  Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain , 1996, The Journal of experimental medicine.

[20]  P. Krammer,et al.  Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. , 1995, Blood.

[21]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[22]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[23]  P. Kleihues,et al.  Astrocytomas Expression of Fas/apo-1 during the Progression of Updated Version Citing Articles E-mail Alerts Expression of Fas/apo-1 during the Progression of Astrocytomas , 2022 .

[24]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[25]  O. G. Dodge,et al.  Histological Typing of tumours of the Central Nervous System , 1981, British Journal of Cancer.

[26]  K. Koretz,et al.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[27]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[28]  Erwin G. Van Meir,et al.  Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.

[29]  P. Kelly,et al.  Grading of astrocytomas: A simple and reproducible method , 1988, Cancer.

[30]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[31]  L. French,et al.  Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover , 1996, The Journal of cell biology.

[32]  N. Copeland,et al.  The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. , 1992, Journal of immunology.

[33]  J. Tschopp,et al.  Activated B cells express functional Fas ligand , 1996, European journal of immunology.

[34]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[35]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.